EiRx, BioMérieux Pen PGx Alliance to Validate Each Other’s Dx, Rx Biomarkers | GenomeWeb
NEW YORK (GenomeWeb News) — EiRx Therapeutics and BioMérieux today said they plan to validate the diagnostic and therapeutic potential of their candidate tumor markers.
Terms of the alliance call for BioMérieux to see if proteins in EiRx’s biomarker panel can become components in new diagnostics for colorectal cancer. Meanwhile, EiRx will use its siRNA-driven platform to test BioMérieux’s colorectal biomarker panel as targets for new drug therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.